An interventional study of Gene-alteration pair (G-A) in Cancer, sponsored by Grand Hôpital de Charleroi. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Grand Hôpital de Charleroi · Not applicable, Interventional, and Diagnostic
The pathological anatomy laboratory, which is managed by the IPG, would involve monitoring patients being treated for cancer and receiving care at the GHDC in order to take blood samples from those in whom the presence of plasma ctDNA carrying a mutation in a specific gene is suspected - a mutation detectable by the TST79 test.
The development of targeted therapies in oncology requires the regular implementation of new tests. Routine clinical analyses currently focus mainly on tumour tissue, but analyses of blood components - particularly plasma - or other biological fluids from patients with cancer are gaining clinical significance in light of advances in molecular biology techniques and knowledge in oncology.
The laboratory wishes to offer patients with cancer sequencing of circulating free DNA (ctDNA) in plasma using a commercial test developed by Illumina. This test can detect various types of mutations (point mutations, small deletions or insertions, loss or gain of gene copy number, and gene fusions) in 79 genes (TST79 test).
9,610 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.
This study's planned enrollment of 15 is below the median of 50 across 7,429 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Grand Hôpital de Charleroi is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Genetic: Gene-alteration pair (G-A)
Genetic: Gene-alteration pair (G-A)
Genetic: Gene-alteration pair (G-A)
Genetic: Gene-alteration pair (G-A)
Genetic: Gene-alteration pair (G-A)
Genetic: Gene-alteration pair (G-A)
Genetic: Gene-alteration pair (G-A)
Point mutations, small insertions or deletions (indels), gene fusions, copy number amplifications.
To validate and accredit the TST79 test on plasma samples within the hospital's pathology laboratory
The aim is to extend tumour DNA sequencing to circulating tumour DNA (ctDNA), which is present in the plasma of cancer patients.
Time frame: Through study completion, an average of two years
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Grand Hôpital de Charleroi